Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
出版年份 2020 全文链接
标题
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
作者
关键词
-
出版物
Cancers
Volume 12, Issue 7, Pages 1862
出版商
MDPI AG
发表日期
2020-07-10
DOI
10.3390/cancers12071862
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
- (2020) Pei-Chang Lee et al. Cancers
- Immune-based therapies for hepatocellular carcinoma
- (2020) David J. Pinato et al. ONCOGENE
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
- (2019) Swetha Kambhampati et al. CANCER
- Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
- (2019) Kazuomi Ueshima et al. Cancers
- Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients
- (2019) Francesco Tovoli et al. JOURNAL OF HEPATOLOGY
- 747PA phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
- (2019) J Llovet et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
- (2019) Petros Fessas et al. IMMUNOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
- (2019) Lin Xu et al. TRANSPLANTATION PROCEEDINGS
- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
- (2018) Michael J Flynn et al. HEPATOLOGY
- Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use
- (2017) Yuan-Hung Kuo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
- (2017) David J. Pinato et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis
- (2017) Alessandro Granito et al. LANCET ONCOLOGY
- Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma
- (2017) Pei-Chang Lee et al. LIVER INTERNATIONAL
- Medical Management of Hepatocellular Carcinoma
- (2017) Nicole E. Rich et al. Journal of Oncology Practice
- Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization
- (2017) Bin Gui et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Whishful thinking or Possible?
- (2016) Joerg Trojan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma
- (2016) Anthony W H Chan et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma
- (2016) Anna Pecorelli et al. LIVER INTERNATIONAL
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
- (2015) Alessandro Granito et al. Therapeutic Advances in Gastroenterology
- The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series
- (2014) Eleonora Terzi et al. DIGESTIVE DISEASES
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
- (2014) Agustín Albillos et al. JOURNAL OF HEPATOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Immunotherapy of hepatocellular carcinoma
- (2012) Angela D. Pardee et al. OncoImmunology
- Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
- (2009) Puneeta Tandon et al. LIVER INTERNATIONAL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started